HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Analyst Earnings Estimates
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.096M 1,669.14% | 900K -70.93% | 2.087M 131.89% | 9.444M 352.52% | 23.735M 151.32% | 46.123M 94.32% | |
| EBITDA YoY % growth | -10.19M -126.65% | -11.312M -11.01% | -15.497M -37.00% | -15.736M -1.54% | -11.999M 23.75% | 4.02M 133.50% | |
| EBIT YoY % growth | -10.327M -103.41% | -11.508M -11.44% | -15.846M -37.70% | -11.931M 24.70% | 1.72M 114.42% | 34.555M 1,909.01% | |
| Operating Margin | -333.56% | -1,278.67% | -759.27% | -126.34% | 7.25% | 74.92% | |
| EPS YoY % growth | N/A 74.27% | N/A -2.27% | N/A -26.67% | -0.56 2.34% | -0.42 25.75% | -0.54 -28.23% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 4.153M 576.38% | % | ||
| Q4 2023 Q2Q % growth | 927K 3.00% | % | ||
| Q2 2023 Q2Q % growth | 614K -40.56% | % | ||
| Q4 2022 Q2Q % growth | 900K -60.14% | % | ||
| Q2 2022 Q2Q % growth | 1.033M 23.27% | % | ||
| Q4 2021 Q2Q % growth | 2.258M 2,327.96% | % | ||
| Q2 2021 Q2Q % growth | 838K 4,310.53% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 0% |
| Revenue | N/A | N/A | 0% | 10.44% |